e-learning
resources
Munich 2014
Sunday, 07.09.2014
Markers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of tiotropium bromide on collagen-IV level: Results from 180-days study in subjects with moderate COPD
M. Ostrovskyy, M. Kulynych-Miskiv, I. Savelikhina, O. Varunkiv (Ivano-Frankivsk, Ukraine)
Source:
International Congress 2014 – Markers
Session:
Markers
Session type:
Thematic Poster Session
Number:
563
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Ostrovskyy, M. Kulynych-Miskiv, I. Savelikhina, O. Varunkiv (Ivano-Frankivsk, Ukraine). Effect of tiotropium bromide on collagen-IV level: Results from 180-days study in subjects with moderate COPD. Eur Respir J 2014; 44: Suppl. 58, 563
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
Effect of tiotropium bromide on IFN-γ level: Results from 180-days study in moderate COPD patients with viral-induced exacerbations in anamnesis
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
Effect of aclidinium bromide on dyspnoea and health status in patients with stable COPD: Phase III data by GOLD 2013 classification
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Effect of roflumilast on lung function: Results from 180-days study in subjects With severe COPD
Source: Annual Congress 2013 –COPD mechanisms
Year: 2013
Estimation of tiotropium efficacy at the COPD patients with group D
Source: International Congress 2015 – Different data in COPD
Year: 2015
Stable state MR-proadrenomedullin level in COPD patients; a validation study
Source: International Congress 2014 – Comorbidities
Year: 2014
The relationship between 24-hour symptoms and COPD exacerbations: Results from ASSESS
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
LATE-BREAKING ABSTRACT: Effect of fluticasone furoate (FF)/vilanterol (VI) on the rate of COPD exacerbations in everyday clinical practice: Results of the COPD Salford lung study (SLS)
Source: International Congress 2016 – Best abstracts in asthma and COPD
Year: 2016
Clinical, functional and laboratory assessment of treatment efficacy in COPD patients
Source: International Congress 2014 – Predictors
Year: 2014
Effects of aclidinium bromide/formoterol fumarate fixed-dose combination on health status in COPD
Source: International Congress 2014 – COPD markers
Year: 2014
Onbrace: A real-life evaluation of indacaterol maintenance treatment for COPD
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Implications of under treatment of stable COPD (SAVING study)
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
Phenotypical heterogeneity of severe COPD subjects: Baseline results from the Czech multicentre research database of COPD
Source: International Congress 2015 – Monitoring and phenotyping COPD
Year: 2015
Effectiveness of indacaterol with or without tiotropium in patients with moderate or severe chronic obstructive pulmonary disease (COPD) - the GOLDEN II study
Source: International Congress 2014 – Diagnosis and treatment of COPD in primary care
Year: 2014
The effect of tiotropium bromide on lung function parameters in patients with asthma- COPD overlap syndrome
Source: International Congress 2016 – Asthma points to ponder
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept